COVID-19 Pandemic Impact: Global R&D Spend For AI in Healthcare and Pharmaceuticals Will Increase US$1.5 Billion By 2025

image
ABI Research whitepaper identifies the short-and long-term impacts the global pandemic will have on Artificial Intelligence and Machine Learning
15 Apr 2020

The Coronavirus outbreak has proven that healthcare institutions can no longer ignore the role of Artificial Intelligence (AI) in their daily workflow. AI spending in the healthcare and pharmaceutical industries is expected to increase from US$463 million in 2019 to more than US$2 billion over the next 5 years, states global tech market advisory firm, ABI Research.

“Artificial Intelligence is playing a key role in responding to the pandemic,” says Lian Jye Su, Principal Analyst at ABI Research. Several companies, including Alibaba, YITU, Graphen, and Google DeepMind, are already developing AI tools to help detect the virus, diagnose its evolution, track its geographical footprint, project its future, and even predict its potential protein structure to find a vaccine for it.

Aside from viral detection, AI will be adopted in the field of bioinformatics, where the Ribonucleic Acid (RNA) sequence of COVID-19 can be thoroughly analyzed to develop the right antiviral drugs. “Now, no single drug can combat the virus effectively. In order to get ahead of the ever-evolving virus and to save as many lives as possible, new drug discovery, development, and testing processes need to be set up, as the conventional method is no longer suitable,” Su explains. Tools from established companies like Google DeepMind, startups like Graphen, and AI chipsets from vendors like NVIDIA and Intel will help accelerate the speed of drug discovery, development, and testing, allowing pharmaceutical companies and healthcare authorities to combat the pandemic.

Pharmaceutical companies and healthcare authorities will take lessons from the current chaotic situation, and anticipate universal programs and frameworks to better manage pandemic situations, predict the emergence and the spread of viruses, and, most importantly, find a cure for them in a timely fashion. The situation will encourage healthcare agencies, pharmaceutical vendors, and webscale companies to enhance their Research and Development (R&D) investments in AI as a core technology for enabling these initiatives.

Global R&D expenditures for the pharmaceutical industry are estimated to be between US$180 billion and US$195 billion in 2022. AI spending in the healthcare and pharmaceutical industries is expected to increase from US$463 million in 2019 to more than US$2 billion by 2025. “The pharmaceutical industry is a significant market that AI hardware and software vendors should target,” Su advises.

For a clearer picture of the current and future ramifications of COVID-19 across technologies and industries, download the whitepaper Taking Stock of COVID-19: The Short- and Long-Term Ramifications on Technology and End Markets.

 

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research 是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact ABI Research

Media Contacts

Americas: +1.516.624.2542
Europe: +44.(0).203.326.0142
Asia: +65 6950.5670

Related Service